1. Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR.
EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. (A) Histological and amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) confirmation of a patient (number 3) with EGFR exon 19 deletion: hematoxylin and eosin (H&E) staining at ×10 magnification. Scale bar, 100 μm. Immunohistochemistry for total-EGFR, phosphorylated EGFR (phospho-EGFR), and E746-A750del–specific EGFR at ×20 magnification from inset in (B). Scale bars, 50 μm. ARMS PCR: ΔCt = < 26 (cutoff). (B) Histological and ARMS PCR confirmation of a patient (number 36) with EGFR exon 21 L858R point mutation: H&E staining at ×10 magnification. Scale bar, 100 μm. Immunohistochemistry for total-EGFR, phospho-EGFR, and L858R-specific EGFR at ×20 magnification from inset in (B). Scale bars, 50 μm. ARMS PCR: ΔCt = < 26 (cutoff). (C) Histological and ARMS PCR confirmation of a patient (number 54) with wild-type EGFR: H&E staining at ×10 magnification. Scale bar, 100 μm. Immunohistochemistry for total-EGFR, phospho-EGFR, and E746-A750 del–specific EGFR at ×20 magnification from inset in (C). Scale bars, 50 μm. ARMS PCR: ΔCt = 113 > 26 (cutoff).
Xilin Sun et al., Sci Transl Med 2018;10:eaan8840
Published by AAAS